Navigation Links
Isis Initiates Phase 1 Studies with Isis-GCGRRx and Isis-GCCRRx to Treat Type 2 Diabetes
Date:11/2/2011

ovascular, metabolic and severe and rare/neurodegenerative diseases, and cancer.  Isis' partner, Genzyme, plans to commercialize Isis' lead product, mipomersen, following regulatory approval, which is expected in 2012.  Isis' patents provide strong and extensive protection for its drugs and technology.  Additional information about Isis is available at www.isispharm.com.

ISIS PHARMACEUTICALS' FORWARD-LOOKING STATEMENT

This press release includes forward-looking statements regarding Isis Pharmaceuticals and the discovery, development and potential of ISIS-GCGRRx and ISIS-GCCRRx for the treatment of type 2 diabetes.  Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs, including the planned commercialization of mipomersen, is a forward-looking statement and should be considered an at-risk statement.  Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.  Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements.  Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis.  As a result, you are cautioned not to rely on these forward-looking statements.  These and other risks concerning Isis' programs are described in additional detail in Isis' annual report on Form 10-K for the year ended December 31, 2010 and its most recent quarterly report on Form 10-Q, which are on file with the SEC. Copies of these and other document
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Bionovo Initiates Menerba (MF101) Phase 3 Clinical Trial for Menopausal Hot Flashes
2. Elusys Initiates Third Clinical Safety Study of Anthim, a New Anthrax Treatment; Company Successfully Completes Manufacturing at Commercial Scale
3. CryoLife Initiates Enrollment in U.S. Clinical Trial for BioFoam®
4. CareFusion Initiates Class I Recall of EnVe Ventilators
5. Takeda Initiates Phase 3 Clinical Trial Program in the United States, Latin America, and Europe for Investigational Type 2 Diabetes Therapy TAK-875
6. ChemoCentryx Initiates Phase II Clinical Trial for CCX168, a Novel Small Molecule C5aR Antagonist for the Treatment of Vasculitis
7. Merrimack Pharmaceuticals Initiates Enrollment in a Neoadjuvant Phase 2 Study of MM-121 with Paclitaxel in HER2-negative Breast Cancer Patients
8. Adamas Pharmaceuticals Initiates a Phase 2/3 Clinical Study of ADS-5102 for Parkinsons Disease
9. Pharmasset Initiates QUANTUM, a Phase 2b Interferon-Free Trial of PSI-7977 and PSI-938 for All HCV Genotypes
10. Nektar Initiates Second Phase 1 Clinical Study Evaluating NKTR-181, A Novel Opioid Molecule, for Treatment of Chronic Pain
11. Omthera Pharmaceuticals, Inc. Initiates Phase III ESPRIT Trial of Add-on Epanovaâ„¢ to Statin Therapy in Patients with Hypertriglyceridemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 Shire plc (LSE: SHP, NASDAQ: ... of Fair Trading (OFT) approval condition to the announced tender offer ...   As a result of the waiver, the transaction ... complete the tender offer on January 24, 2014 following the currently ...
(Date:1/15/2014)... 2014 Tegra Medical is very pleased to announce the ... new Chief Executive Officer.  Mark was promoted from his current ... the company,s four facilities in Massachusetts , ... joined Tegra Medical in 2012 with 20+ years of broad-based ...
(Date:1/15/2014)... 2014 Reportlinker.com announces that a new ... catalogue: Insulin Pump ... http://www.reportlinker.com/p01957812/Insulin-Pump-Market--Forecast-–-Worldwide-Analysis.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Equipment_and_Supply ... Insulin Pumps are gaining strong acceptance ...
Breaking Medicine Technology:Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17
... Calif., April 24, 2012  A dose of 10 milligrams (mg) ... fermented soy germ-based nutritional supplement is as effective as a ... significantly and is even more effective for relieving muscle and ... women published in the June Journal of Women,s Health ...
... April 24, 2012  The Intellectual Property & Science ... to support R&D pharmaceutical leaders with a new ... use by AstraZeneca executives. The rich visualization dashboard ... , the company,s flagship life sciences platform, ...
Cached Medicine Technology:Soy-Based S-equol Supplement Reduces Hot Flash Frequency, Muscle And Joint Pain In U.S. Postmenopausal Women 2Soy-Based S-equol Supplement Reduces Hot Flash Frequency, Muscle And Joint Pain In U.S. Postmenopausal Women 3Soy-Based S-equol Supplement Reduces Hot Flash Frequency, Muscle And Joint Pain In U.S. Postmenopausal Women 4Soy-Based S-equol Supplement Reduces Hot Flash Frequency, Muscle And Joint Pain In U.S. Postmenopausal Women 5Soy-Based S-equol Supplement Reduces Hot Flash Frequency, Muscle And Joint Pain In U.S. Postmenopausal Women 6Soy-Based S-equol Supplement Reduces Hot Flash Frequency, Muscle And Joint Pain In U.S. Postmenopausal Women 7Soy-Based S-equol Supplement Reduces Hot Flash Frequency, Muscle And Joint Pain In U.S. Postmenopausal Women 8Thomson Reuters Launches New Mobile Oncology Decision Support Solution for R&D Pharmaceutical Leaders 2
(Date:4/16/2014)... 16, 2014): Celldex Therapeutics, Inc. (NASDAQ: CLDX) announced ... of CDX-1401 in solid tumors, including long-term patient follow-up, ... (Vol 6 Issue 232). The data demonstrate robust antibody ... in patients with very advanced cancers and suggest that ...
(Date:4/16/2014)... , DOWNERS GROVE, Ill. April 16, 2014 ... of surveillance colonoscopy in average-risk patients with one to ... about 90 percent of cases. This may be an ... multicenter endoscopic database study to quantify adherence to guidelines ...
(Date:4/15/2014)... in the United States have nearly doubled since 1988, suggests ... Health, with obesity apparently to blame for the surge. The ... not hit all groups equally, with alarming increases in diabetes ... research reported in the April 15, 2014 issue of the ...
(Date:4/15/2014)... a decades-old medical mystery and in the process have found ... kill about 1.5 million people a year. The researchers say they ... that has been in use for more than 50 years ... it is to the microbes it attacks. , A report ...
(Date:4/15/2014)... California, San Diego School of Medicine have identified a mechanism ... liver disease and why the virus is able to persist ... pathogen, which infects an estimated 200 million people worldwide, attacks ... the cell,s innate ability to fight infection. It does this ...
Breaking Medicine News(10 mins):Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 2Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 3Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 4Health News:Surveillance colonoscopy recommendations for average-risk patients with 1 to 2 small polyps consistent with guidelines 2Health News:Surveillance colonoscopy recommendations for average-risk patients with 1 to 2 small polyps consistent with guidelines 3Health News:Pre-diabetes and diabetes nearly double over the past 2 decades 2Health News:Potent, puzzling and (now less) toxic: Team discovers how antifungal drug works 2Health News:Potent, puzzling and (now less) toxic: Team discovers how antifungal drug works 3Health News:Breaking bad mitochondria 2
... China Healthcare Acquisition Corp. (the "Company") (NYSE Alternext ... meeting held today, March 5, 2009, its stockholders voted ... early distribution of the Company,s trust fund for the ... March 5, 2009. Today,s vote had the automatic effect ...
... FRANKLIN, Tenn., March 5 /PRNewswire/ -- ... services, today announced details for the release of its financial ... plans to issue its earnings release for the fourth quarter ... March 25, 2009, and will host a conference call on ...
... not getting services they need to prevent another attack, ... After suffering a stroke, the chances of having another ... aren,t getting the interventions they need to reduce that ... smoking cessation and exercise, and medical treatments, such as ...
... the Aspen Health Stewardship Project will unveil a new ... support of a roadmap for making smart, sustainable improvements ... which includes patient groups, and health employer and provider ... America by adopting a set of core principles to ...
... Re-enrollment OpportunitiesHARRISBURG, Pa., March 5 Insurance ... laid off from a job that offered health insurance ... provide them with relief on premiums and that now ... information."I want to let Pennsylvanians know that additional help ...
... it has received a $76 million grant from the Bill ... and young child nutrition in developing countries in Africa and ... to increase rates of exclusive breastfeeding and improve complementary feeding ... children die and millions more are permanently disabled as a ...
Cached Medicine News:Health News:China Healthcare Acquisition Corp. Announces Stockholder Approval of Charter Amendment to Permit Early Distribution of Its Trust Fund and to Permit Its Continued Existence Without Blank Check Company Provisions and Sets Payment Date 2Health News:Second Stroke Prevention Efforts Found Wanting 2Health News:Second Stroke Prevention Efforts Found Wanting 3Health News:Aspen Institute to Introduce Roadmap for Responsible Health Care Reform, New Coalition To Call For Sustainable Improvements 2Health News:Pennsylvanians Encouraged to Take Another Look at COBRA Options 2Health News:AED Receives Gates Foundation Grant to Improve Nutrition and Reduce Deaths Among Young Children in Developing Countries 2
...
...
... biomechanical properties influence the results and ... and may hold clues to diagnosing ... assessing the biomechanical properties of corneal ... practitioners and researchers to measuring purely ...
The Surgiflex WAVE is a comfortable, easy to use, versatile, and interchangeable suction-irrigation device....
Medicine Products: